TELO (Telomir Pharmaceuticals) Total Liabilities: $0.83 Mil (As of Mar. 2026)


TELO Telomir Pharmaceuticals Inc TELO
14 GF Score
Price $1.24
! 3 Warning Signs
View Full Analysis

What is Telomir Pharmaceuticals Total Liabilities?

Telomir Pharmaceuticals TELO +0.40% 14 Total Liabilities is $0.83 Mil as of Mar. 2026. GuruFocus rates TELO with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Telomir Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was $0.83 Mil.

Telomir Pharmaceuticals's quarterly Total Liabilities increased from Sep. 2025 ($0.42 Mil) to Dec. 2025 ($1.43 Mil) but then declined from Dec. 2025 ($1.43 Mil) to Mar. 2026 ($0.83 Mil).

Telomir Pharmaceuticals's annual Total Liabilities declined from Dec. 2023 ($1.34 Mil) to Dec. 2024 ($0.68 Mil) but then increased from Dec. 2024 ($0.68 Mil) to Dec. 2025 ($1.43 Mil).


Telomir Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Telomir Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telomir Pharmaceuticals Total Liabilities Chart

Telomir Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
0.14 0.99 1.34 0.68 1.43

Telomir Pharmaceuticals Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.35 0.42 1.43 0.83
TELO
14GF Score
Telomir Pharmaceuticals Inc TELO
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Telomir Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Telomir Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=7.341-5.913
=1.43

Telomir Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=5.79-4.962
=0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $0.83 Mil mean?
Telomir Pharmaceuticals (TELO) has a Total Liabilities of $0.83 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Telomir Pharmaceuticals and its competitors.
Is Telomir Pharmaceuticals' Total Liabilities too high?
Telomir Pharmaceuticals' current Total Liabilities is $0.83 Mil. Overall, Telomir Pharmaceuticals has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Telomir Pharmaceuticals' Total Liabilities compare to MAIA and LONA?
Telomir Pharmaceuticals' Total Liabilities of $0.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Telomir Pharmaceuticals and its competitors. Telomir Pharmaceuticals's current Total Liabilities is $0.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telomir Pharmaceuticals stock overvalued right now?
Telomir Pharmaceuticals (TELO) has a current Total Liabilities of $0.83 Mil. The current Total Liabilities is $0.83 Mil. Telomir Pharmaceuticals' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Telomir Pharmaceuticals (TELO), the current Total Liabilities is $0.83 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Telomir Pharmaceuticals Business Description

Address 100 SE, 2nd Street, Suite 2000, No.1009, Miami, FL, USA, 33131
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
14GF Score

Get the complete analysis for TELO

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.24
Price